GlassScriptPhysician profile
Mario A Ochoa
NPI 1851393615
$27,963.77
in general payments reported to CMS, 2019-2025
61 companies · $4,871 in 2025
The $4,871 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,238 · 2020: $3,453 · 2021: $3,781 · 2022: $3,099 · 2023: $4,785 · 2024: $3,738 · 2025: $4,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $254 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,080.72 |
| Education | $253.51 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,769.70 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Corcept Therapeutics | $2,744.79 | 2020-2025 | Korlym |
| Glaxosmithkline, LLC. | $1,903.58 | 2019-2025 | Nucala, Shingrix, Arexvy |
| Novo Nordisk INC | $1,799.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,709.18 | 2019-2025 | Repatha, Otezla, Tezspire |
| Lilly USA, LLC | $1,298.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,119.07 | 2019-2025 | |
| Mannkind Corporation | $1,069.89 | 2019-2025 | Afrezza |
| Janssen Pharmaceuticals, INC | $1,047.60 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $984.78 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.23 | 2019-2024 | Ofev, Synjardy, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $719.83 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $715.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $496.77 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $436.05 | 2020-2025 | Caplyta |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Ochoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.